1 min read
Add as a preferred source on GoogleAbbVie Raises Full-Year Guidance as Non-GAAP EPS Beats Estimates
Third-quarter revenue reached $17.4 billion, up 10.3% year over year, while the immunology portfolio generated $9.165 billion in global net revenue.
AbbVie raised its full-year guidance after third-quarter revenue and non-GAAP earnings per share beat estimates, with its immunology portfolio also posting higher global net revenue.
Revenue totaled $17.4 billion, up 10.3% from a year earlier and $50 million above estimates. Non-GAAP earnings per share was $3.82, exceeding estimates by $0.05.
The immunology portfolio generated $9.165 billion in global net revenue during the quarter, a 16.3% increase on a reported basis.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.